- Home
- RCKY vs TRVI Comparison
RCKY vs TRVI Comparison
Compare RCKY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- TRVI
- Stock Information
- Founded
- RCKY 1932
- TRVI 2011
- Country
- RCKY United States
- TRVI United States
- Employees
- RCKY N/A
- TRVI N/A
- Industry
- RCKY Shoe Manufacturing
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- TRVI Health Care
- Exchange
- RCKY Nasdaq
- TRVI Nasdaq
- Market Cap
- RCKY 224.2M
- TRVI 227.2M
- IPO Year
- RCKY 1993
- TRVI 2019
- Fundamental
- Price
- RCKY $30.69
- TRVI $3.02
- Analyst Decision
- RCKY Hold
- TRVI Strong Buy
- Analyst Count
- RCKY 2
- TRVI 7
- Target Price
- RCKY $28.00
- TRVI $9.57
- AVG Volume (30 Days)
- RCKY 41.0K
- TRVI 461.2K
- Earning Date
- RCKY 10-30-2024
- TRVI 11-07-2024
- Dividend Yield
- RCKY 2.08%
- TRVI N/A
- EPS Growth
- RCKY 60.94
- TRVI N/A
- EPS
- RCKY 1.99
- TRVI N/A
- Revenue
- RCKY $462,730,000.00
- TRVI N/A
- Revenue This Year
- RCKY $1.34
- TRVI N/A
- Revenue Next Year
- RCKY $5.68
- TRVI N/A
- P/E Ratio
- RCKY $14.92
- TRVI N/A
- Revenue Growth
- RCKY N/A
- TRVI N/A
- 52 Week Low
- RCKY $11.78
- TRVI $0.97
- 52 Week High
- RCKY $40.14
- TRVI $4.00
- Technical
- Relative Strength Index (RSI)
- RCKY 48.98
- TRVI 45.08
- Support Level
- RCKY $29.48
- TRVI $3.00
- Resistance Level
- RCKY $32.01
- TRVI $3.50
- Average True Range (ATR)
- RCKY 1.16
- TRVI 0.27
- MACD
- RCKY -0.03
- TRVI -0.05
- Stochastic Oscillator
- RCKY 41.69
- TRVI 27.17
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract. It generates majority of the revenue from Wholesale segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.